NewAmsterdam Pharma Co N.V.
NAMSW· Nasdaq
Released May 8, 2024, after the close
10-Q filed May 8, 2024, 38 days after period end · 0000950170-24-055767
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $1.40M | $8.63M |
| Net Income | -$93.77M | -$42.02M |
| EPS Diluted | -$1.06 | -$0.51 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NewAmsterdam Pharma Co N.V. · CIK 1936258 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end